NO962637L - 2,4-disulfonylfenylbutylnitron, salter derav og anveldelse som farmasöytiske midler - Google Patents

2,4-disulfonylfenylbutylnitron, salter derav og anveldelse som farmasöytiske midler

Info

Publication number
NO962637L
NO962637L NO962637A NO962637A NO962637L NO 962637 L NO962637 L NO 962637L NO 962637 A NO962637 A NO 962637A NO 962637 A NO962637 A NO 962637A NO 962637 L NO962637 L NO 962637L
Authority
NO
Norway
Prior art keywords
nervous system
central nervous
pharmaceutical agents
salts
disulfonylphenylbutylnitrone
Prior art date
Application number
NO962637A
Other languages
English (en)
Other versions
NO306457B1 (no
NO962637D0 (no
Inventor
John M Carney
Original Assignee
Oklahoma Med Res Found
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found, Univ Kentucky Res Found filed Critical Oklahoma Med Res Found
Publication of NO962637D0 publication Critical patent/NO962637D0/no
Publication of NO962637L publication Critical patent/NO962637L/no
Publication of NO306457B1 publication Critical patent/NO306457B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/46—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO962637A 1993-12-23 1996-06-20 2,4-disulfonylfenylbutylnitron, salter derav, farmasöytisk sammensetning, samt anvendelse av denne forbindelse til fremstilling av et medikament NO306457B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/173,579 US5488145A (en) 1993-12-23 1993-12-23 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
PCT/US1994/014545 WO1995017876A2 (en) 1993-12-23 1994-12-22 2,4-disulphophenyl butylnitrone, its salts, and their use as pharmaceutical spintraps

Publications (3)

Publication Number Publication Date
NO962637D0 NO962637D0 (no) 1996-06-20
NO962637L true NO962637L (no) 1996-08-13
NO306457B1 NO306457B1 (no) 1999-11-08

Family

ID=22632663

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962637A NO306457B1 (no) 1993-12-23 1996-06-20 2,4-disulfonylfenylbutylnitron, salter derav, farmasöytisk sammensetning, samt anvendelse av denne forbindelse til fremstilling av et medikament

Country Status (28)

Country Link
US (4) US5488145A (no)
EP (1) EP0736004B1 (no)
JP (3) JP3412821B2 (no)
KR (1) KR100370522B1 (no)
CN (1) CN1070176C (no)
AT (1) ATE192736T1 (no)
AU (1) AU679835B2 (no)
BR (2) BR9408378A (no)
CA (1) CA2179521C (no)
CZ (1) CZ289629B6 (no)
DE (1) DE69424441T2 (no)
DK (1) DK0736004T3 (no)
ES (1) ES2145264T3 (no)
FI (1) FI111718B (no)
GR (1) GR3034134T3 (no)
HR (1) HRP950358B1 (no)
HU (1) HU221167B1 (no)
MY (1) MY114178A (no)
NO (1) NO306457B1 (no)
NZ (1) NZ279025A (no)
PL (1) PL185189B1 (no)
PT (1) PT736004E (no)
RU (1) RU2159231C2 (no)
SG (1) SG64903A1 (no)
SK (1) SK282403B6 (no)
TW (1) TW299315B (no)
UA (1) UA45964C2 (no)
WO (1) WO1995017876A2 (no)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723502A (en) * 1985-07-18 1998-03-03 Proctor; Peter H. Topical spin trap composition and method
US5622994A (en) * 1989-10-17 1997-04-22 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
EP0496796B1 (en) * 1989-10-17 1994-08-31 Oklahoma Medical Research Foundation Method and compositions for inhibition of disorders associated with oxidative damage
US6002001A (en) * 1991-06-18 1999-12-14 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
US20050107366A1 (en) * 1991-06-18 2005-05-19 Carney John M. Spin trapping pharmaceutical compositions and methods for use thereof
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
DE69634647T2 (de) * 1995-09-11 2006-03-02 Aventis Pharmaceuticals Inc. Cyclische Nitrone und pharmazeutische Mittel die sie enthalten
WO1997019054A1 (en) 1995-11-17 1997-05-29 Florida International University Azulenyl nitrone spin trapping agents, methods of making and using same
EP0949915A4 (en) * 1996-04-17 2001-07-04 Oklahoma Med Res Found TREATMENT OF DEMENTIA ASSOCIATED WITH AIDS VIRUS INFECTION (HIV-1) USING NITRONE-FREE RADICAL TRAPS
EP1021430A1 (en) * 1996-07-19 2000-07-26 Centaur Pharmaceuticals, Inc. Furan nitrone compounds
TW429241B (en) * 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
MA26553A1 (fr) * 1997-10-17 2004-12-20 Centaur Pharmaceuticals Inc Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
NZ505757A (en) * 1998-01-16 2002-09-27 Centaur Pharmaceuticals Inc Thioether furan nitrone compounds and pharmaceuticals thereof; useful for the treatment or prophylaxis of neurodegenerative, autoimmune and inflammatory conditions
JP2002509147A (ja) * 1998-01-16 2002-03-26 センター ファーマシューティカルズ， インコーポレイテッド チオフェンニトロン化合物
US6255353B1 (en) * 1998-03-13 2001-07-03 Centaur Pharmaceuticals, Inc. Inhibition of angiogenesis
US6083989A (en) * 1999-05-18 2000-07-04 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
CA2333190A1 (en) * 1998-05-19 1999-11-25 Beverly Greenwood-Van Meerveld Furan nitrone therapeutics for the treatment of inflammatory bowel disease
US6730700B2 (en) * 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
UA66401C2 (en) 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
EP1155019B1 (en) 1999-01-25 2005-12-07 National Jewish Medical and Research Center Substituted porphyrins and their therapeutic use
NZ543319A (en) * 1999-04-28 2007-06-29 Neurochem Int Ltd Compositions and methods for treating amyloidosis using sulphonate derivatives
BR9904931A (pt) * 1999-10-18 2001-06-12 Sergio Teixeira Ferreira Inibição de amiloidoses
US6815425B1 (en) 1999-10-22 2004-11-09 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical composition containing pGLU-GLU-PRO-NH2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
AU1574701A (en) * 1999-10-22 2001-04-30 Wrair Walter Reed Army Institute Of Research A pharmaceutical composition containing pglu-glu-pro-nh2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
WO2001051459A1 (en) * 2000-01-10 2001-07-19 Centaur Phamaceuticals, Inc. Method for the purification of aryl sulfonic acids and salts
SE0000056D0 (sv) 2000-01-10 2000-01-10 Astrazeneca Ab Novel process
SE0000055D0 (sv) 2000-01-10 2000-01-10 Centaur Pharmaceuticals Inc Novel process
SE0001916D0 (sv) * 2000-05-23 2000-05-23 Astrazeneca Ab Novel formulation
US6664297B1 (en) 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
WO2002065993A2 (en) 2001-01-08 2002-08-29 Centaur Pharmaceuticals, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
WO2003010154A1 (en) * 2001-07-26 2003-02-06 Samsung Electronics Co. Ltd. Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
FR2846968B1 (fr) * 2002-11-08 2005-02-04 Salles Jean Pierre Nouveaux derives amphiphiles de l'alpha-c-phenyl-n-tert- butyl nitrone
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20050059638A1 (en) * 2003-08-04 2005-03-17 Kelly Michael G. Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
BRPI0517790A (pt) * 2004-11-12 2008-10-21 Neurochem Int Ltd métodos e composições fluoradas para tratar doenças relacionadas à amilóide
CA2586334A1 (en) * 2004-11-16 2006-06-08 Neurochem (International) Limited Compounds for the treatment of cns and amyloid associated diseases
WO2006085149A2 (en) 2004-12-22 2006-08-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20060235370A1 (en) * 2005-04-04 2006-10-19 Oblong John E Method of regulating mammalian keratinous tissue
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
WO2007013843A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxide against myocardial ischaemia
WO2007013844A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-[(tert-butylimino)benzene-1,3-disulfonate n-oxide against nausea
WO2007013841A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-((tert-butylimine)methyl) benzene-1,3-disulfonate n-oxide against cerebral oedema
WO2007013842A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-((tert-butylimino)methyl) benzene-1,3-disulfonate n-oxide against maemorrhagic changes in the brain
MX2008008213A (es) * 2005-12-22 2008-09-03 Neurochem Int Ltd Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias.
WO2008013866A2 (en) * 2006-07-25 2008-01-31 Hough Ear Institute Methods for treating acute acoustic trauma
KR101608445B1 (ko) 2006-10-12 2016-04-01 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
EP2120905A1 (en) * 2006-12-22 2009-11-25 BELLUS Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
US20090082454A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched disufenton
US8425593B2 (en) 2007-09-26 2013-04-23 St. Jude Medical, Inc. Collapsible prosthetic heart valves
EP2242360B1 (en) * 2008-02-12 2015-04-08 Tosk, Inc. Doxorubicin adjuvants to reduce toxicity and methods for using the same
US11382895B2 (en) * 2008-05-23 2022-07-12 National Jewish Health Methods for treating injury associated with exposure to an alkylating species
ES2398339T3 (es) * 2008-09-02 2013-03-15 Oklahoma Medical Research Foundation 2,4-disulfonil fenil terc-butil nitrona para el tratamiento de gliomas
AU2010289838C1 (en) * 2009-08-24 2014-03-06 Hough Ear Institute Methods for treating acute acoustic trauma
ES2893825T3 (es) 2011-02-04 2022-02-10 Hough Ear Inst Métodos de tratamiento de lesiones cerebrales
JP2019537582A (ja) 2016-10-31 2019-12-26 ハフ イアー インスティテュート シナプス形成および神経突起形成を増強するための方法
EP3570826A4 (en) 2017-01-19 2020-09-23 Otologic Pharmaceutics, Inc. N-ACETYLCYSTEIN FORMULATIONS AND THEIR USES
US11660280B2 (en) 2017-09-20 2023-05-30 Oklahoma Medical Research Foundation Treatment of drug resistant gliomas
US10829441B2 (en) 2017-11-14 2020-11-10 The University Of Toledo Reactive oxygen species-sensitive nitric oxide synthase inhibitors for the treatment of ischemic stroke
WO2019213245A1 (en) 2018-05-03 2019-11-07 Hough Ear Institute Methods for reducing accumulated pathologic tau protein
KR102899320B1 (ko) 2018-09-12 2025-12-12 호 이어 인스티튜트 인공 와우 수술에 따른 난청의 치료 방법
WO2021173702A1 (en) * 2020-02-24 2021-09-02 Oblato, Inc. Compositions and methods for treating cancer and tumor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3914650A1 (de) * 1989-05-03 1990-11-08 Basf Ag Neue phenylendiamine sowie ein verfahren zur herstellung von phenylendiaminen
EP0496796B1 (en) * 1989-10-17 1994-08-31 Oklahoma Medical Research Foundation Method and compositions for inhibition of disorders associated with oxidative damage
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
US5025032A (en) * 1989-10-17 1991-06-18 Oklahoma Medical Research Foundation Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
DE3937342A1 (de) * 1989-11-09 1991-05-16 Bayer Ag Verfahren zur herstellung von 2-aminobenzol-disulfonsaeuren-(1,4) und die neue verbindung 6-chlor-2-aminobenzol-disulfonsaeure-(1,4)
EP0590072B1 (en) * 1991-06-18 2001-12-05 Oklahoma Medical Research Foundation Use of spin trapping for the treatment of diseases associated with oxidation of lipids and proteins
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps

Also Published As

Publication number Publication date
US5780510A (en) 1998-07-14
BR1100626A (pt) 1999-11-23
FI111718B (fi) 2003-09-15
WO1995017876A3 (en) 1995-08-10
RU2159231C2 (ru) 2000-11-20
KR100370522B1 (ko) 2003-05-16
CN1070176C (zh) 2001-08-29
JPH09507232A (ja) 1997-07-22
HUT76788A (en) 1997-11-28
WO1995017876A2 (en) 1995-07-06
NO306457B1 (no) 1999-11-08
GR3034134T3 (en) 2000-11-30
CA2179521C (en) 2002-03-19
ES2145264T3 (es) 2000-07-01
JP2004075696A (ja) 2004-03-11
HRP950358B1 (en) 2001-04-30
DK0736004T3 (da) 2000-10-09
NZ279025A (en) 1998-02-26
US5488145A (en) 1996-01-30
HRP950358A2 (en) 1997-08-31
JP3412821B2 (ja) 2003-06-03
CZ177596A3 (en) 1996-12-11
HU9601739D0 (en) 1996-08-28
PL315154A1 (en) 1996-10-14
SK78896A3 (en) 1997-09-10
ATE192736T1 (de) 2000-05-15
SK282403B6 (sk) 2002-01-07
UA45964C2 (uk) 2002-05-15
JP2001010953A (ja) 2001-01-16
PL185189B1 (pl) 2003-03-31
US5475032A (en) 1995-12-12
AU679835B2 (en) 1997-07-10
CZ289629B6 (cs) 2002-03-13
DE69424441T2 (de) 2000-10-12
BR9408378A (pt) 1997-08-19
FI962589L (fi) 1996-08-20
SG64903A1 (en) 1999-05-25
TW299315B (no) 1997-03-01
HK1008294A1 (en) 1999-05-07
AU1552795A (en) 1995-07-17
FI962589A0 (fi) 1996-06-20
NO962637D0 (no) 1996-06-20
DE69424441D1 (de) 2000-06-15
HK1001768A1 (en) 1998-07-10
EP0736004A1 (en) 1996-10-09
EP0736004B1 (en) 2000-05-10
CN1156447A (zh) 1997-08-06
PT736004E (pt) 2000-09-29
CA2179521A1 (en) 1995-07-06
MY114178A (en) 2002-08-30
US5508305A (en) 1996-04-16
HU221167B1 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
NO962637D0 (no) 2,4-disulfonylfenylbutylnitron, salter derav og anveldelse som farmasöytiske midler
DE69331409D1 (de) Oral 1alpha-hydroxyprevitamin d
NZ512883A (en) 2-oxoquinoline compounds and medicinal uses thereof
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
CL2008003941A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden compulsivo obsesivo.
PT998287E (pt) Utilizacao de levobupivacaina
CA2377174A1 (en) Oral administration forms for administering a fixed tramadol and diclofenac combination
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
ES2147788T3 (es) 3,4-diarilcromanos para el tratamiento de la dermatitis.
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
ES2159362T3 (es) Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
NO955313D0 (no) Anvendelse av ropivacain i fremstillingen av et farmasöytikum med analgetisk effekt som har minimal motorisk blokkering
DK0742716T3 (da) Farmaceutisk sammensætning til systemisk transdermal indgivelse med det aktive middel morphin-6-glucuronid
ES2184121T3 (es) Formulacion para el tratamiento y/o profilaxis de la demencia.
AR035986A1 (es) Uso de derivados anti-convulsivos para la manufactura de un medicamento util para el tratamiento del temblor esencial
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine
BR0112874A (pt) Uso de fribratos para a preparação de um medicamento útil no tratamento de falha de coração congestiva